BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shi X, Xing H, Yang X, Li F, Yao S, Congwei J, Zhao H, Hacker M, Huo L, Li X. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging 2021;48:1593-603. [PMID: 33097975 DOI: 10.1007/s00259-020-05070-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen H, Teng M, Zhang H, Liang X, Cheng H, Liu G. Advanced radionuclides in diagnosis and therapy for hepatocellular carcinoma. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.079] [Reference Citation Analysis]
2 Li M, Younis MH, Zhang Y, Cai W, Lan X. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05706-y] [Reference Citation Analysis]
3 Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, Guan Y, Jia H, Chen J, Lu L, Xie F, Qin L. 68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. Front Oncol 2021;11:693640. [PMID: 34249748 DOI: 10.3389/fonc.2021.693640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Jiang D, Chen X, You Z, Wang H, Zhang X, Li X, Ren S, Huang Q, Hua F, Guan Y, Zhao J, Xie F. Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. Eur J Nucl Med Mol Imaging 2021. [PMID: 34297193 DOI: 10.1007/s00259-021-05441-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zheng S, Lin R, Chen S, Zheng J, Lin Z, Zhang Y, Xue Q, Chen Y, Zhang J, Lin K, You X, Yao S, Miao W. Characterization of the benign lesions with increased 68Ga-FAPI-04 uptake in PET/CT. Ann Nucl Med 2021;35:1312-20. [PMID: 34424505 DOI: 10.1007/s12149-021-01673-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kuyumcu S, Sanli Y, Subramaniam RM. Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management. Front Oncol 2021;11:758958. [PMID: 34858834 DOI: 10.3389/fonc.2021.758958] [Reference Citation Analysis]
7 Treglia G, Muoio B, Roustaei H, Kiamanesh Z, Aryana K, Sadeghi R. Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F]F-FDG in Oncology: A Systematic Review. Int J Mol Sci 2021;22:11192. [PMID: 34681850 DOI: 10.3390/ijms222011192] [Reference Citation Analysis]
8 Siripongsatian D, Promteangtrong C, Kunawudhi A, Kiatkittikul P, Boonkawin N, Chinnanthachai C, Jantarato A, Chotipanich C. Comparisons of Quantitative Parameters of Ga-68-Labelled Fibroblast Activating Protein Inhibitor (FAPI) PET/CT and [18F]F-FDG PET/CT in Patients with Liver Malignancies. Mol Imaging Biol 2022. [PMID: 35486293 DOI: 10.1007/s11307-022-01732-2] [Reference Citation Analysis]
9 Wu Z, Hua Y, Shen Q, Yu C. Research progress on the role of fibroblast activation protein in diagnosis and treatment of cancer. Nucl Med Commun 2022. [PMID: 35506275 DOI: 10.1097/MNM.0000000000001565] [Reference Citation Analysis]
10 Peng D, He J, Liu H, Cao J, Wang Y, Chen Y. FAPI PET/CT research progress in digestive system tumours. Dig Liver Dis 2021:S1590-8658(21)00380-7. [PMID: 34364808 DOI: 10.1016/j.dld.2021.07.011] [Reference Citation Analysis]
11 Gilardi L, Airò Farulla LS, Demirci E, Clerici I, Omodeo Salè E, Ceci F. Imaging Cancer-Associated Fibroblasts (CAFs) with FAPi PET. Biomedicines 2022;10:523. [DOI: 10.3390/biomedicines10030523] [Reference Citation Analysis]
12 Dendl K, Koerber SA, Kratochwil C, Cardinale J, Finck R, Dabir M, Novruzov E, Watabe T, Kramer V, Choyke PL, Haberkorn U, Giesel FL. FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis? Cancers (Basel) 2021;13:4946. [PMID: 34638433 DOI: 10.3390/cancers13194946] [Reference Citation Analysis]
13 Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021. [PMID: 34173007 DOI: 10.1007/s00259-021-05475-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Siripongsatian D, Promteangtrong C, Kunawudhi A, Kiatkittikul P, Chotipanich C. 68Ga-FAPI-46 PET/MR Detects Recurrent Cholangiocarcinoma and Intraductal Papillary Mucinous Neoplasm in a Patient Showing Increasing CEA with Negative 18F-FDG PET/CT and Conventional CT. Nucl Med Mol Imaging 2021;55:257-60. [PMID: 34721719 DOI: 10.1007/s13139-021-00712-8] [Reference Citation Analysis]
15 Li Y, Lin X, Li Y, Lv J, Hou P, Liu S, Chen P, Wang M, Zhou C, Wang X. Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study. Mol Imaging Biol 2021. [PMID: 34816283 DOI: 10.1007/s11307-021-01679-w] [Reference Citation Analysis]
16 Şahin E, Elboğa U, Çelen YZ, Sever ÖN, Çayırlı YB, Çimen U. Comparison of 68Ga-DOTA-FAPI and 18FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer. Eur J Radiol 2021;142:109867. [PMID: 34315086 DOI: 10.1016/j.ejrad.2021.109867] [Reference Citation Analysis]
17 Ruan Q, Feng J, Jiang Y, Zhang X, Duan X, Wang Q, Yin G, Xiao D, Zhang J. Preparation and Bioevaluation of 99mTc-Labeled FAP Inhibitors as Tumor Radiotracers to Target the Fibroblast Activation Protein. Mol Pharm 2022;19:160-71. [PMID: 34904839 DOI: 10.1021/acs.molpharmaceut.1c00712] [Reference Citation Analysis]
18 Lan L, Zhang S, Xu T, Liu H, Wang W, Feng Y, Wang L, Chen Y, Qiu L. Prospective Comparison of 68Ga-FAPI versus 18F-FDG PET/CT for Tumor Staging in Biliary Tract Cancers. Radiology 2022;:213118. [PMID: 35579524 DOI: 10.1148/radiol.213118] [Reference Citation Analysis]